These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31490391)

  • 1. Predictors for improvement of xerostomia in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.
    Pan XB; Liu Y; Huang ST; Chen KH; Jiang YM; Zhu XD
    Medicine (Baltimore); 2019 Sep; 98(36):e17030. PubMed ID: 31490391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Pan XB; Liu Y; Li L; Qu S; Chen L; Liang SX; Chen KH; Liang ZG; Zhu XD
    Aging (Albany NY); 2020 Jan; 12(2):1857-1866. PubMed ID: 32005029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram for predicting late radiation-induced xerostomia among locoregionally advanced nasopharyngeal carcinoma in intensity modulated radiation therapy era.
    Yang K; Xie W; Zhang X; Wang Y; Shou A; Wang Q; Tian J; Yang J; Li G
    Aging (Albany NY); 2021 Jul; 13(14):18645-18657. PubMed ID: 34282056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient- and therapy-related factors associated with the incidence of xerostomia in nasopharyngeal carcinoma patients receiving parotid-sparing helical tomotherapy.
    Lee TF; Liou MH; Ting HM; Chang L; Lee HY; Wan Leung S; Huang CJ; Chao PJ
    Sci Rep; 2015 Aug; 5():13165. PubMed ID: 26289304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parotid gland radiation dose-xerostomia relationships based on actual delivered dose for nasopharyngeal carcinoma.
    Lou J; Huang P; Ma C; Zheng Y; Chen J; Liang Y; Li H; Yin Y; Liu D; Yu G; Li D
    J Appl Clin Med Phys; 2018 May; 19(3):251-260. PubMed ID: 29664218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy.
    Li M; Zhang J; Zha Y; Li Y; Hu B; Zheng S; Zhou J
    BMC Oral Health; 2022 Jun; 22(1):239. PubMed ID: 35715856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis.
    Sommat K; Hussain A; Ong WS; Yit NLF; Khoo JBK; Soong YL; Wee JTS; Fong KW; Tan TWK
    Radiother Oncol; 2019 Sep; 138():149-157. PubMed ID: 31265972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.
    Zhou J; Wang L; Qiu T; Gao H; Wang L; Huang S; He X; Wu L
    BMC Cancer; 2024 May; 24(1):648. PubMed ID: 38802747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Value of Intensity Modulated Radiation Therapy in Alleviating Parotid Gland Function Injury in Patients with Stage N0 Nasopharyngeal Carcinoma from Physical and Dosimetric Aspects.
    Zheng L; Wang H; Yang N; Du F; Xiao L; Wu G
    Comput Math Methods Med; 2022; 2022():4651364. PubMed ID: 35860184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.
    Huang H; Miao J; Xiao X; Hu J; Zhang G; Peng Y; Lu S; Liang Y; Huang S; Han F; Deng X; Zhao C; Wang L
    Radiother Oncol; 2022 Oct; 175():1-9. PubMed ID: 35817320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dynamic observation on the short-term change of xerostomia after intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma].
    Li Y; Zhao C
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 50(1):33-7. PubMed ID: 25764925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy.
    Zheng Y; Han F; Xiao W; Xiang Y; Lu L; Deng X; Cui N; Zhao C
    Radiat Oncol; 2015 Jan; 10():17. PubMed ID: 25582731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter to the editor of radiotherapy and oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study." by Huang et al.
    Sarode GS; Sarode SC; Anand R
    Radiother Oncol; 2022 Dec; 177():252. PubMed ID: 36334695
    [No Abstract]   [Full Text] [Related]  

  • 15. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
    Zhao DW; Teng F; Meng LL; Fan WJ; Luo YR; Jiang HY; Chen NX; Zhang XX; Yu W; Cai BN; Zhao LJ; Wang PG; Ma L
    Radiother Oncol; 2023 Jul; 184():109683. PubMed ID: 37120102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal Evolution of Parotid Volume and Parotid Apparent Diffusion Coefficient in Nasopharyngeal Carcinoma Patients Treated by Intensity-Modulated Radiotherapy Investigated by Magnetic Resonance Imaging: A Pilot Study.
    Juan CJ; Cheng CC; Chiu SC; Jen YM; Liu YJ; Chiu HC; Kao HW; Wang CW; Chung HW; Huang GS; Hsu HH
    PLoS One; 2015; 10(8):e0137073. PubMed ID: 26323091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Zhao DW; Fan WJ; Fang XM; Luo YR; Wei J; Chen NX; Zhang XX; Liu G; Li JF; Zang X; Li M; Meng L; Ma L
    Radiother Oncol; 2022 Jul; 172():91-98. PubMed ID: 35584742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer.
    Marucci L; Marzi S; Sperduti I; Giovinazzo G; Pinnarò P; Benassi M; Strigari L
    Head Neck; 2012 Mar; 34(3):328-35. PubMed ID: 21400632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.